Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome

G. Paragh, I. Seres, M. Harangi, Annamária Erdei, Mária Audikovszky, Lóránd Debreczeni, Anna Kovácsay, László Illyés, Gyula Pados

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aims: Diabetic dyslipidaemia with decreased high-density lipoprotein-cholesterol (HDL-C) concentration plays a key role in enhanced atherosclerosis. The antioxidant effect of HDL is due to the influence of human paraoxonase 1 (PON1) and several authors have described decreased activity of this enzyme in Type 2 diabetics and subjects with metabolic syndrome. The goal of this study was to examine the effect of daily ciprofibrate on serum PON1 and lipoprotein concentrations in patients with metabolic syndrome. Methods: Fifty-one patients with metabolic syndrome were enrolled into the study. We examined the effect of 100 mg day-1 ciprofibrate treatment on lipid concentrations, oxidized low-density lipoprotein (LDL), PON1 concentrations and activity. We also investigated the calculated size of LDL-cholesterol (LDL-C). Results: During the 3-month study, it was observed that following treatment with ciprofibrate, the serum triglyceride concentration decreased significantly (from 2.76 ± 0.9 mmol l-1 to 2.27 ± 1.6 mmol l-1; -18%; P <0.001), while HDL-C increased significantly (from 0.95 ± 0.2 mmol l-1 to 1.2 ± 0.3 mmol l-1; 26%; P <0.001). The oxidatively modified LDL-C concentration decreased significantly (from 137 ± 19 U l-1 to 117 ± 20 U l-1; P <0.001), while HDL-associated apolipoprotein A1 significantly increased (from 1.35 ± 0.2 g l-1 to 1.75 ± 0.3 g l-1; P <0.001). The LDL-C/LDL-apoB ratio, which reflects the size of LDL, increased significantly (from 0.96 ± 0.05 to 1.05 ± 0.06; P <0.05). Serum PON1 activity was significantly elevated (from 108 ± 34 U l-1 to 129 ± 31 U l-1; P <0.05), while standardized values for HDL-C remained significantly unchanged (PON1/HDL-C) (from 114 ± 21 to 107 ± 20; NS). Conclusion: Three months of treatment with ciprofibrate favourably affected the lipid profile, increased LDL resistance to oxidation and improved antioxidant status by increasing serum paraoxonase activity in these patients.

Original languageEnglish
Pages (from-to)694-701
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume61
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Aryldialkylphosphatase
LDL Lipoproteins
HDL Cholesterol
Serum
Antioxidants
Lipids
Apolipoprotein A-I
Apolipoproteins B
Dyslipidemias
LDL Cholesterol
Lipoproteins
ciprofibrate
Atherosclerosis
Triglycerides
Therapeutics
Enzymes

Keywords

  • Ciprofibrate
  • Hyperlipidaemia
  • Metabolic syndrome
  • Paraoxonase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. / Paragh, G.; Seres, I.; Harangi, M.; Erdei, Annamária; Audikovszky, Mária; Debreczeni, Lóránd; Kovácsay, Anna; Illyés, László; Pados, Gyula.

In: British Journal of Clinical Pharmacology, Vol. 61, No. 6, 06.2006, p. 694-701.

Research output: Contribution to journalArticle

Paragh, G. ; Seres, I. ; Harangi, M. ; Erdei, Annamária ; Audikovszky, Mária ; Debreczeni, Lóránd ; Kovácsay, Anna ; Illyés, László ; Pados, Gyula. / Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. In: British Journal of Clinical Pharmacology. 2006 ; Vol. 61, No. 6. pp. 694-701.
@article{1b10ed769ebf42ef82e418b365bd3f96,
title = "Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome",
abstract = "Aims: Diabetic dyslipidaemia with decreased high-density lipoprotein-cholesterol (HDL-C) concentration plays a key role in enhanced atherosclerosis. The antioxidant effect of HDL is due to the influence of human paraoxonase 1 (PON1) and several authors have described decreased activity of this enzyme in Type 2 diabetics and subjects with metabolic syndrome. The goal of this study was to examine the effect of daily ciprofibrate on serum PON1 and lipoprotein concentrations in patients with metabolic syndrome. Methods: Fifty-one patients with metabolic syndrome were enrolled into the study. We examined the effect of 100 mg day-1 ciprofibrate treatment on lipid concentrations, oxidized low-density lipoprotein (LDL), PON1 concentrations and activity. We also investigated the calculated size of LDL-cholesterol (LDL-C). Results: During the 3-month study, it was observed that following treatment with ciprofibrate, the serum triglyceride concentration decreased significantly (from 2.76 ± 0.9 mmol l-1 to 2.27 ± 1.6 mmol l-1; -18{\%}; P <0.001), while HDL-C increased significantly (from 0.95 ± 0.2 mmol l-1 to 1.2 ± 0.3 mmol l-1; 26{\%}; P <0.001). The oxidatively modified LDL-C concentration decreased significantly (from 137 ± 19 U l-1 to 117 ± 20 U l-1; P <0.001), while HDL-associated apolipoprotein A1 significantly increased (from 1.35 ± 0.2 g l-1 to 1.75 ± 0.3 g l-1; P <0.001). The LDL-C/LDL-apoB ratio, which reflects the size of LDL, increased significantly (from 0.96 ± 0.05 to 1.05 ± 0.06; P <0.05). Serum PON1 activity was significantly elevated (from 108 ± 34 U l-1 to 129 ± 31 U l-1; P <0.05), while standardized values for HDL-C remained significantly unchanged (PON1/HDL-C) (from 114 ± 21 to 107 ± 20; NS). Conclusion: Three months of treatment with ciprofibrate favourably affected the lipid profile, increased LDL resistance to oxidation and improved antioxidant status by increasing serum paraoxonase activity in these patients.",
keywords = "Ciprofibrate, Hyperlipidaemia, Metabolic syndrome, Paraoxonase",
author = "G. Paragh and I. Seres and M. Harangi and Annam{\'a}ria Erdei and M{\'a}ria Audikovszky and L{\'o}r{\'a}nd Debreczeni and Anna Kov{\'a}csay and L{\'a}szl{\'o} Illy{\'e}s and Gyula Pados",
year = "2006",
month = "6",
doi = "10.1111/j.1365-2125.2006.02565.x",
language = "English",
volume = "61",
pages = "694--701",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome

AU - Paragh, G.

AU - Seres, I.

AU - Harangi, M.

AU - Erdei, Annamária

AU - Audikovszky, Mária

AU - Debreczeni, Lóránd

AU - Kovácsay, Anna

AU - Illyés, László

AU - Pados, Gyula

PY - 2006/6

Y1 - 2006/6

N2 - Aims: Diabetic dyslipidaemia with decreased high-density lipoprotein-cholesterol (HDL-C) concentration plays a key role in enhanced atherosclerosis. The antioxidant effect of HDL is due to the influence of human paraoxonase 1 (PON1) and several authors have described decreased activity of this enzyme in Type 2 diabetics and subjects with metabolic syndrome. The goal of this study was to examine the effect of daily ciprofibrate on serum PON1 and lipoprotein concentrations in patients with metabolic syndrome. Methods: Fifty-one patients with metabolic syndrome were enrolled into the study. We examined the effect of 100 mg day-1 ciprofibrate treatment on lipid concentrations, oxidized low-density lipoprotein (LDL), PON1 concentrations and activity. We also investigated the calculated size of LDL-cholesterol (LDL-C). Results: During the 3-month study, it was observed that following treatment with ciprofibrate, the serum triglyceride concentration decreased significantly (from 2.76 ± 0.9 mmol l-1 to 2.27 ± 1.6 mmol l-1; -18%; P <0.001), while HDL-C increased significantly (from 0.95 ± 0.2 mmol l-1 to 1.2 ± 0.3 mmol l-1; 26%; P <0.001). The oxidatively modified LDL-C concentration decreased significantly (from 137 ± 19 U l-1 to 117 ± 20 U l-1; P <0.001), while HDL-associated apolipoprotein A1 significantly increased (from 1.35 ± 0.2 g l-1 to 1.75 ± 0.3 g l-1; P <0.001). The LDL-C/LDL-apoB ratio, which reflects the size of LDL, increased significantly (from 0.96 ± 0.05 to 1.05 ± 0.06; P <0.05). Serum PON1 activity was significantly elevated (from 108 ± 34 U l-1 to 129 ± 31 U l-1; P <0.05), while standardized values for HDL-C remained significantly unchanged (PON1/HDL-C) (from 114 ± 21 to 107 ± 20; NS). Conclusion: Three months of treatment with ciprofibrate favourably affected the lipid profile, increased LDL resistance to oxidation and improved antioxidant status by increasing serum paraoxonase activity in these patients.

AB - Aims: Diabetic dyslipidaemia with decreased high-density lipoprotein-cholesterol (HDL-C) concentration plays a key role in enhanced atherosclerosis. The antioxidant effect of HDL is due to the influence of human paraoxonase 1 (PON1) and several authors have described decreased activity of this enzyme in Type 2 diabetics and subjects with metabolic syndrome. The goal of this study was to examine the effect of daily ciprofibrate on serum PON1 and lipoprotein concentrations in patients with metabolic syndrome. Methods: Fifty-one patients with metabolic syndrome were enrolled into the study. We examined the effect of 100 mg day-1 ciprofibrate treatment on lipid concentrations, oxidized low-density lipoprotein (LDL), PON1 concentrations and activity. We also investigated the calculated size of LDL-cholesterol (LDL-C). Results: During the 3-month study, it was observed that following treatment with ciprofibrate, the serum triglyceride concentration decreased significantly (from 2.76 ± 0.9 mmol l-1 to 2.27 ± 1.6 mmol l-1; -18%; P <0.001), while HDL-C increased significantly (from 0.95 ± 0.2 mmol l-1 to 1.2 ± 0.3 mmol l-1; 26%; P <0.001). The oxidatively modified LDL-C concentration decreased significantly (from 137 ± 19 U l-1 to 117 ± 20 U l-1; P <0.001), while HDL-associated apolipoprotein A1 significantly increased (from 1.35 ± 0.2 g l-1 to 1.75 ± 0.3 g l-1; P <0.001). The LDL-C/LDL-apoB ratio, which reflects the size of LDL, increased significantly (from 0.96 ± 0.05 to 1.05 ± 0.06; P <0.05). Serum PON1 activity was significantly elevated (from 108 ± 34 U l-1 to 129 ± 31 U l-1; P <0.05), while standardized values for HDL-C remained significantly unchanged (PON1/HDL-C) (from 114 ± 21 to 107 ± 20; NS). Conclusion: Three months of treatment with ciprofibrate favourably affected the lipid profile, increased LDL resistance to oxidation and improved antioxidant status by increasing serum paraoxonase activity in these patients.

KW - Ciprofibrate

KW - Hyperlipidaemia

KW - Metabolic syndrome

KW - Paraoxonase

UR - http://www.scopus.com/inward/record.url?scp=33646945008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646945008&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2006.02565.x

DO - 10.1111/j.1365-2125.2006.02565.x

M3 - Article

C2 - 16722831

AN - SCOPUS:33646945008

VL - 61

SP - 694

EP - 701

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -